KK2845 / Kyowa Kirin - LARVOL DELTA

Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Kyowa Kirin Co., Ltd. | N=48 ➔ 72 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Enrollment change • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML. (PubMed, Leukemia) - "The pharmacokinetics of KK2845 in cynomolgus monkey after intravenous infusion demonstrated a favorable profile. Taken together, these data suggest that KK2845 could be a novel ADC therapeutic in AML."

Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • HAVCR2

Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Kyowa Kirin Co., Ltd.

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

KK2845, A PBD DIMER-CONTAINING ANTIBODY-DRUG CONJUGATE TARGETING TIM-3-EXPRESSING LEUKEMIA STEM CELLS OF AML (EHA 2024) - "Preclinical studies suggest that KK2845 exhibits potent anti-leukemia activity with both payload and ADCC-based activity, but do not affect normal hematopoiesis. These data support the clinical evaluation of KK2845 asa new drug candidate for the treatment of AML."

Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • CTSB • HAVCR2